The influence of previous hormone therapy on PSA response in prostate cancer patients (PTS) failing first-line androgen ablation

被引：0
|
作者：
Rassweiler, J [1 ]
机构：
[1] STADTKRANKENHAUS HEILBRONN,HEILBRONN,GERMANY
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [21] First-line therapy for "high-risk prostate cancer"
    Rexer, H.
    UROLOGE, 2014, 53 (07): : 1063 - 1064
  • [22] Should ablation be first-line therapy and for whom: The antagonist position - Response
    Verma, A
    Natale, A
    CIRCULATION, 2005, 112 (08) : 1230 - 1230
  • [23] Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy
    Broyelle, Antonin
    Delanoy, Nicolas
    Bimbai, Andre-Michel
    Le Deley, Marie-Cecile
    Penel, Nicolas
    Villers, Arnauld
    Lebellec, Loic
    Oudard, Stephane
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 349 - +
  • [24] PSA half life and psa doubling time as a predictor of response to androgen deprivation therapy for metastatic prostate cancer
    Park, Yong Hyun
    Park, Dong Soo
    Jeong, Chang Wook
    Ku, Ja Hyun
    Kwak, Cheol
    Kim, Hyeon Hoe
    JOURNAL OF UROLOGY, 2008, 179 (04): : 185 - 185
  • [25] Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tripathi, N.
    Chigarira, B.
    Sayegh, N.
    Thomas, V. Mathew
    Kumar, S. Adidam
    Goel, D.
    Tandar, C.
    Mcfarland, T. R.
    Nussenzveig, R.
    Sirohi, D.
    Swami, U.
    Maughan, B. L.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1184 - S1184
  • [26] Multiple rechallenges (ReCs) with docetaxel (DOC) as an option after first-line therapy in patients (pts) with castration-resistant prostate cancer (CRPC)
    Caffo, O.
    Brugnara, S.
    Caldara, A.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Veccia, A.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [27] MODELING PROSTATE CANCER RESPONSE TO CONTINUOUS VERSUS INTERMITTENT ANDROGEN ABLATION THERAPY
    Jain, Harsh Vardhan
    Friedman, Avner
    DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B, 2013, 18 (04): : 945 - 967
  • [28] Intermittent versus continuous androgen deprivation therapy in hormone sensitive low volume metastatic prostate cancer with deep PSA response
    Hakeem, Muhammad Usman
    Jacques, Angela
    Ye, Linda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 36 - 37
  • [29] Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer
    Huebner, Nicolai A.
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2020, 77 (01) : 132 - 133
  • [30] First-line Therapy for Metastatic Castration-sensitive Prostate Cancer
    Lau, Y. H.
    Wan, L. Y.
    Lam, M. H. C.
    HONG KONG JOURNAL OF RADIOLOGY, 2022, 25 (03): : 244 - 245
12345